Jane L. Grogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jane L. Grogan has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Baharak Bahmani
Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - Carolyn Offutt
Genentech Research and Early Development, 1 DNA Way, South San Francisco, 94080, CA, USA
2 shared publications Eugene Y. Chiang
Department of Cancer Immunology, Genentech, South San Francisco, CA, USA
2 shared publications- Indira Guleria
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA
2 shared publications - John C Davis
Genentech Research and Early Development, 1 DNA Way, South San Francisco, 94080, CA, USA
2 shared publications Jonathan S. Bromberg
2 shared publications
Latest Publications
- Open Access
- 8 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing
- 8 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Open AccessRepetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing
- Open Access
- 12 July 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (13)
Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing
The contribution of the kidney-draining lymph node (KLN) to the pathogenesis of ischemia-reperfusion injury (IRI) of the kidney and its subsequent recovery has not been explored in depth. In addition, the mechanism by which repetitive IRI contributes to renal fibrosis remains poorly understood. Herein, we have found that IRI of the kidney is associated with expansion of high endothelial venules (HEVs) and activation of fibroblastic reticular cells (FRCs) in the KLN, as demonstrated by significant expansion in the extracellular matrix. The lymphotoxin α signaling pathway mediates activation of FRCs, and chronic treatment with lymphotoxin β receptor–immunoglobulin fusion protein (LTβr-Ig) resulted in marked alteration of the KLN as well as augmentation of renal fibrosis. Depletion of FRCs reduced T cell activation in the KLN and ameliorated renal injury in acute IRI. Repetitive renal IRI was associated with senescence of FRCs, fibrosis of the KLN, and renal scarring, which were ameliorated by FRC administration. Therefore, our study emphasizes the critical role of FRCs in both the initiation and repair phases of injury following IRI of the kidney.
- 12 July 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (13)
Open AccessRepetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing
The contribution of the kidney-draining lymph node (KLN) to the pathogenesis of ischemia-reperfusion injury (IRI) of the kidney and its subsequent recovery has not been explored in depth. In addition, the mechanism by which repetitive IRI contributes to renal fibrosis remains poorly understood. Herein, we have found that IRI of the kidney is associated with expansion of high endothelial venules (HEVs) and activation of fibroblastic reticular cells (FRCs) in the KLN, as demonstrated by significant expansion in the extracellular matrix. The lymphotoxin α signaling pathway mediates activation of FRCs, and chronic treatment with lymphotoxin β receptor–immunoglobulin fusion protein (LTβr-Ig) resulted in marked alteration of the KLN as well as augmentation of renal fibrosis. Depletion of FRCs reduced T cell activation in the KLN and ameliorated renal injury in acute IRI. Repetitive renal IRI was associated with senescence of FRCs, fibrosis of the KLN, and renal scarring, which were ameliorated by FRC administration. Therefore, our study emphasizes the critical role of FRCs in both the initiation and repair phases of injury following IRI of the kidney.
- 1 January 2017
- Published by Elsevier in Trends in Immunology
- Vol. 38 (1) , 20-28
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- 1 January 2017
- Published by Elsevier in Trends in Immunology
- Vol. 38 (1) , 20-28
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- Open Access
- 16 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S1) , 73-221
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
- 16 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (S1) , 73-221
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
- 2 April 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (9) , e1036214
The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses
Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory receptor TIGIT in antitumor and other chronic CD8+ T cell responses.
- 2 April 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (9) , e1036214
The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses
Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory receptor TIGIT in antitumor and other chronic CD8+ T cell responses.
- Top Cited Papers
- 1 December 2014
- Published by Elsevier in Cancer Cell
- Vol. 26 (6) , 923-937
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- 1 December 2014
- Published by Elsevier in Cancer Cell
- Vol. 26 (6) , 923-937
Top Cited PapersThe Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- Open Access
- 30 October 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (5) , 467
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
- 30 October 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (5) , 467
Open AccessEfficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
- Open Access
- 18 November 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (49) , 19896-19901
Dimerization of LTβR by LTα1β2is necessary and sufficient for signal transduction
Significance: Cytokines are proteins that modulate the activity of target cells via activation of cell-surface receptors. The trimeric cytokines of the tumor necrosis factor superfamily typically signal by inducing homotrimerization of their cognate receptors. We use structural and biophysical approaches to show that the unique heterotrimeric tumor necrosis factor superfamily member Lymphotoxin (LT)α1β2induces dimerization rather than trimerization of the LTβ Receptor (LTβR). Cellular signaling assays were used to show that dimerization of LTβR is sufficient to activate intracellular signaling processes. Furthermore, disruption of receptor interactions at either site prevents signaling via LTβR, challenging the existing paradigm that trimeric complexes are required for signal transduction by the TNF family cytokines.
- 18 November 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (49) , 19896-19901
Open AccessDimerization of LTβR by LTα1β2is necessary and sufficient for signal transduction
Significance: Cytokines are proteins that modulate the activity of target cells via activation of cell-surface receptors. The trimeric cytokines of the tumor necrosis factor superfamily typically signal by inducing homotrimerization of their cognate receptors. We use structural and biophysical approaches to show that the unique heterotrimeric tumor necrosis factor superfamily member Lymphotoxin (LT)α1β2induces dimerization rather than trimerization of the LTβ Receptor (LTβR). Cellular signaling assays were used to show that dimerization of LTβR is sufficient to activate intracellular signaling processes. Furthermore, disruption of receptor interactions at either site prevents signaling via LTβR, challenging the existing paradigm that trimeric complexes are required for signal transduction by the TNF family cytokines.
- Open Access
- 8 January 2012
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (1) , R6
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Introduction: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For clarity and per AMA/S-W Style, please restore the use of Oxford/serial commas (ie: David likes vanilla, strawberry, and chocolate ice cream) throughout. and biologic activity of single and multiple doses of intravenous (IV) or subcutaneous (SC) pateclizumab in RA patients. Methods: The single ascending dose (SAD) phase in patients with stable RA consisted of six cohorts (4:1 active:placebo at 0.3 mg/kg IV, 1.0 mg/kg IV, 1.0 mg/kg SC, 3.0 mg/kg IV, 3.0 mg/kg SC, and 5.0 mg/kg IV; n = 5/cohort). In the multiple ascending dose (MAD) phase, patients with prespecified RA disease activity received three doses of pateclizumab or placebo (4:1) every 2 weeks (1.0 mg/kg SC, n = 10; 3.0 mg/kg SC, n = 20; or 5.0 mg/kg IV, n = 5). Safety and tolerability were assessed throughout, and clinical activity was determined after three doses (Week 6). Results: We observed no serious adverse events (AEs) or dose-limiting toxicities, and the majority of AEs were mild to moderate. The pharmacokinetic profiles were linear, and clearance was independent of dose. Reductions in levels of serum CXCL13 were observed, supporting the biologic activity of pateclizumab on the LTα pathway. Patients receiving pateclizumab in the 3.0 mg/kg MAD group (3.0 mg/kg SC) demonstrated ACR20, ACR50, and ACR70 response rates at week 6 of 75%, 56% and 25%, respectively, compared with 57%, 29%, and 0% in the placebo group. The median Disease Activity Score in 28 joints, C-reactive protein, reduction was 28% for pateclizumab, versus 8.4% for placebo. Conclusions: Pateclizumabwas generally well-tolerated in RA patients. Preliminary evidence of clinical activity was observed in active RA patients at the dose level targeted for clinical effect.
- 8 January 2012
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (1) , R6
Open AccessSafety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Introduction: Pateclizumab (MLTA3698A) is a humanized mAb against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis. This study was conducted to assess the safety, tolerability, < NOTE: For clarity and per AMA/S-W Style, please restore the use of Oxford/serial commas (ie: David likes vanilla, strawberry, and chocolate ice cream) throughout. and biologic activity of single and multiple doses of intravenous (IV) or subcutaneous (SC) pateclizumab in RA patients. Methods: The single ascending dose (SAD) phase in patients with stable RA consisted of six cohorts (4:1 active:placebo at 0.3 mg/kg IV, 1.0 mg/kg IV, 1.0 mg/kg SC, 3.0 mg/kg IV, 3.0 mg/kg SC, and 5.0 mg/kg IV; n = 5/cohort). In the multiple ascending dose (MAD) phase, patients with prespecified RA disease activity received three doses of pateclizumab or placebo (4:1) every 2 weeks (1.0 mg/kg SC, n = 10; 3.0 mg/kg SC, n = 20; or 5.0 mg/kg IV, n = 5). Safety and tolerability were assessed throughout, and clinical activity was determined after three doses (Week 6). Results: We observed no serious adverse events (AEs) or dose-limiting toxicities, and the majority of AEs were mild to moderate. The pharmacokinetic profiles were linear, and clearance was independent of dose. Reductions in levels of serum CXCL13 were observed, supporting the biologic activity of pateclizumab on the LTα pathway. Patients receiving pateclizumab in the 3.0 mg/kg MAD group (3.0 mg/kg SC) demonstrated ACR20, ACR50, and ACR70 response rates at week 6 of 75%, 56% and 25%, respectively, compared with 57%, 29%, and 0% in the placebo group. The median Disease Activity Score in 28 joints, C-reactive protein, reduction was 28% for pateclizumab, versus 8.4% for placebo. Conclusions: Pateclizumabwas generally well-tolerated in RA patients. Preliminary evidence of clinical activity was observed in active RA patients at the dose level targeted for clinical effect.